Sign inJoin waitlistJoin the waitlist

Harriet Kluger

Director, Yale SPORE in Skin Cancer, Yale Cancer Center · Yale Cancer Center

Credentials: · · ·

History

Yale Cancer Center
Present
Division of Skin and Kidney Cancer · Yale Cancer Center
Present
Yale-New Haven Hospital
Present

Yale Univ Sch of Med
2000–2002
Internal Medicine
University of New Mexico-Main Campus
1993–1995
Yale Univ Sch of Med
1989–1993

Research

Nivolumab plus ipilimumab in advanced melanoma
New England Journal of Medicine · 2013 · 3,387 citations
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Journal of Clinical Oncology · 2014 · 1,880 citations
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
New England Journal of Medicine · 2016 · 992 citations

Mario Sznol
67 papers
DR
David Rimm
54 papers
Veronica Chiang
34 papers
RC
Robert Camp
33 papers
Sarah Weiss
27 papers · 3 as a fellow
Adebowale Adeniran
26 papers
Marcus Bosenberg
25 papers
Kelly Olino
24 papers
Thuy Tran
23 papers · 12 as a fellow
SA
Stephan Ariyan
20 papers
David Schoenfeld
18 papers · 18 as a fellow
Michael Hurwitz
18 papers

Grants

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
National Cancer Institute · P50
Project lead · $703.6K · Yale University
2015–2030
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $774.7K · Yale University
1997–2029
Yale SPORE in Skin Cancer
National Cancer Institute · P50
PI · $20.5M · Yale University
2006–2028
Yale Cancer Center Calabresi Immuno-Oncology Training Program
National Cancer Institute · K12
Contact PI · $6.1M · Yale University
2018–2028

Clinical trials

Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis
Principal investigator · Withdrawn · Phase 2
Yale University
2026–2029
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Principal investigator · Recruiting · Phase 1
Yale University
2025–2027
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Principal investigator · Terminated · Phase 2
Yale University
2022–2025
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Principal investigator · Completed · Phase 1
Yale University
2020–2026